Welcome to our dedicated page for Salarius Pharmaceuticals news (Ticker: SLRX), a resource for investors and traders seeking the latest updates and insights on Salarius Pharmaceuticals stock.
Salarius Pharmaceuticals, Inc. (Symbol: SLRX) is a clinical-stage biopharmaceutical company dedicated to developing innovative cancer treatments. The company’s unique approach targets cancers with high unmet medical needs through two main types of drugs: targeted protein inhibitors and targeted protein degraders. Salarius is currently focused on two primary drug candidates: Seclidemstat (SP-2577) and SP-3164.
Seclidemstat is a small molecule inhibitor designed to modify the activity of proteins involved in gene regulation. It is currently being evaluated in a Phase 1/2 clinical trial for Ewing sarcoma, an aggressive bone and soft tissue cancer. Notably, the trial has shown promising results, with a recent partial response in an additional patient and an objective response rate of 60% among first-relapse Ewing patients treated with the combination of Seclidemstat, Topotecan, and Cyclophosphamide.
The second candidate, SP-3164, is a small molecule protein degrader aimed at targeting and destroying cancer-promoting proteins. This novel approach could offer a new avenue for cancer treatment, potentially overcoming resistance mechanisms that limit the efficacy of standard therapies.
Salarius Pharmaceuticals is committed to advancing its clinical programs and expanding its pipeline through strategic partnerships and collaborations. The company's mission is to develop transformative therapies that can significantly improve the lives of cancer patients.
Latest News:
Salarius Pharmaceuticals presented clinical data on seclidemstat combined with azacitidine for treating higher-risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) at the 2024 European Hematology Association Annual Meeting.
The Phase 1/2 study reported a 43% overall response rate among 14 patients, with a median overall survival of 18.5 months and median event-free survival of 7.2 months.
The study included 16 enrolled patients, with 14 evaluable for efficacy and 15 for toxicity. Dose-limiting toxicity was observed in one patient in the 750mg BID cohort, leading to cohort expansion.
The maximum tolerated dose has not been reached, and the study will proceed to higher dose levels. Salarius believes the adverse events are manageable.
Results are considered promising for patients who have previously failed hypomethylating agent therapy.
Salarius Pharmaceuticals (NASDAQ: SLRX) announced a 1-for-8 reverse stock split effective June 14, 2024. Trading on a split-adjusted basis will begin on June 17, 2024. The reverse split aims to regain compliance with the $1.00 minimum closing bid price required by Nasdaq. This move reduces the number of issued and outstanding shares from approximately 4.7 million to about 0.6 million. Stockholders approved the proposal on May 9, 2024. The reverse split will uniformly affect all stockholders without altering ownership percentages, though cash will be given in lieu of fractional shares. The split does not impact the number of authorized shares or their par values. Equiniti Trust Company is the exchange agent for the split.
FAQ
What is the current stock price of Salarius Pharmaceuticals (SLRX)?
What is the market cap of Salarius Pharmaceuticals (SLRX)?
What does Salarius Pharmaceuticals, Inc. specialize in?
What are the main drug candidates of Salarius Pharmaceuticals?
What is Seclidemstat (SP-2577) used for?
What is SP-3164?
What are the latest achievements of Salarius Pharmaceuticals?
Where can I find the latest news about Salarius Pharmaceuticals?
How does Salarius Pharmaceuticals aim to impact cancer treatment?
Are there any partnerships that Salarius Pharmaceuticals is involved in?
What is the focus of Salarius Pharmaceuticals' pipeline?
How can I invest in Salarius Pharmaceuticals?
